JLGPX
Price
$78.87
Change
+$0.67 (+0.86%)
Updated
Dec 20 closing price
RGACX
Price
$73.42
Change
+$0.65 (+0.89%)
Updated
Dec 23 closing price
Ad is loading...

JLGPX vs RGACX

Header iconJLGPX vs RGACX Comparison
Open Charts JLGPX vs RGACXBanner chart's image
JPMorgan Large Cap Growth R3
Price$78.87
Change+$0.67 (+0.86%)
VolumeN/A
CapitalizationN/A
American Funds Growth Fund of Amer R3
Price$73.42
Change+$0.65 (+0.89%)
VolumeN/A
CapitalizationN/A
JLGPX vs RGACX Comparison Chart
Loading...
View a ticker or compare two or three
VS
JLGPX vs. RGACX commentary
Dec 24, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JLGPX is a StrongBuy and RGACX is a Buy.

FUNDAMENTALS
Fundamentals
RGACX has more cash in the bank: 301B vs. JLGPX (105B). RGACX pays higher dividends than JLGPX: RGACX (0.25) vs JLGPX (0.05). JLGPX was incepted earlier than RGACX: JLGPX (8 years) vs RGACX (23 years). JLGPX is a more actively managed with annual turnover of: 42.00 vs. RGACX (31.00). JLGPX has a lower initial minimum investment than RGACX: JLGPX (0) vs RGACX (250). JLGPX annual gain was more profitable for investors over the last year : 34.04 vs. RGACX (19.33). JLGPX return over 5 years is better than : 96.72 vs. RGACX (45.87).
JLGPXRGACXJLGPX / RGACX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence8 years23 years-
Gain YTD33.88218.919179%
Front LoadN/AN/A-
Min. Initial Investment0250-
Min. Initial Investment IRAN/AN/A-
Net Assets105B301B35%
Annual Yield % from dividends0.050.2518%
Returns for 1 year34.0419.33176%
Returns for 3 years32.513.231,006%
Returns for 5 years96.7245.87211%
Returns for 10 yearsN/A73.03-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
OPTT0.340.02
+7.74%
Ocean Power Technologies
CRBG29.660.57
+1.96%
Corebridge Financial
XBIT6.380.04
+0.63%
XBiotech
MLTX52.170.29
+0.56%
MoonLake Immunotherapeutics
EOLS10.890.02
+0.18%
Evolus